Media coverage about Albireo Pharma (NASDAQ:ALBO) has been trending somewhat positive this week, according to Accern Sentiment. The research group ranks the sentiment of news coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Albireo Pharma earned a media sentiment score of 0.14 on Accern’s scale. Accern also gave press coverage about the biopharmaceutical company an impact score of 46.9478738514327 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near future.
ALBO has been the topic of several recent analyst reports. Zacks Investment Research lowered shares of Albireo Pharma from a “buy” rating to a “hold” rating in a report on Monday, November 13th. Roth Capital initiated coverage on shares of Albireo Pharma in a report on Wednesday, November 15th. They set a “buy” rating and a $92.00 price target on the stock. Cowen reaffirmed a “buy” rating on shares of Albireo Pharma in a report on Friday, November 17th. Wedbush reaffirmed a “buy” rating on shares of Albireo Pharma in a report on Wednesday, January 3rd. Finally, BidaskClub raised shares of Albireo Pharma from a “hold” rating to a “buy” rating in a report on Wednesday, January 31st. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and four have issued a buy rating to the stock. Albireo Pharma presently has an average rating of “Hold” and a consensus target price of $58.25.
Shares of Albireo Pharma (ALBO) opened at $34.68 on Tuesday. Albireo Pharma has a 1-year low of $15.31 and a 1-year high of $39.87.
About Albireo Pharma
Biodel Inc is a specialty biopharmaceutical company. The Company focuses on the development and commercialization of treatments for diabetes. The Company is engaged in developing product candidates by applying its formulation technologies to existing drugs. The Company is engaged in developing room temperature stable glucagon presentations for use as a rescue treatment for diabetes patients experiencing severe hypoglycemia.
Receive News & Ratings for Albireo Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Albireo Pharma and related companies with MarketBeat.com's FREE daily email newsletter.